Sign In
Buy ACRS
$4.42
-0.210 (-4.54%)
At Close: Jun 03, 2026
ACRS Stock Price Increases 220.24%: Why It Happened
04:46pm, Tuesday, 19'th Jan 2021
The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) increased by 220.24% today. This is why it happened.
Aclaris Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 19'th Jan 2021
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today
12:53pm, Tuesday, 19'th Jan 2021
Investors are excited about the biotech's clinical trial results.
Aclaris Therapeutics stock triples after positive data on arthritis treatment
12:13pm, Tuesday, 19'th Jan 2021
Aclaris Therapeutics stock triples after positive data on arthritis treatment
ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
11:26am, Tuesday, 19'th Jan 2021
Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
10:50am, Tuesday, 19'th Jan 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
10:44am, Tuesday, 19'th Jan 2021
Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
07:00am, Tuesday, 15'th Dec 2020
WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
04:01pm, Monday, 16'th Nov 2020
WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
07:00am, Wednesday, 04'th Nov 2020
WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory
Aclaris Therapeutics Inc (NASDAQ:ACRS) Expected to Post Earnings of -$0.26 Per Share
07:14am, Saturday, 22'nd Aug 2020
Equities analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post earnings per share of ($0.26) for the current quarter, according to Zacks. Three analysts have made estimates for Aclaris
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
04:00pm, Thursday, 13'th Aug 2020
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Friday, 07'th Aug 2020
Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
11:00am, Friday, 07'th Aug 2020
•First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid Arthritis •First Subject Dosed in Phase 2a T
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
04:30pm, Thursday, 06'th Aug 2020
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
